Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $1.485B
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| SNL | Ann: Planned Retirement Peter Gill - Executive Finance Director | 21/03/18 | 0 | 75 | |||
|
|||||||
| NME +SNL FSF | Wall Street rebounds: Aus shares to open higher | 21/03/18 | 0 | 121 | |||
|
|||||||
See All Discussions
ASX News